Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on Lung Cancer, and is edited by Drs. Gang Cheng and Timothy Akhurst. Articles will include: FDG PET/CT for lung cancer staging; Lung neoplasms with low FDG avidity; FDG PET/CT evaluation of lung cancer in populations with high prevalence of granulomatous disease; Prognostic value of FDG PET/CT; Genomic characterization of lung cancer and its impact on the use and timing of PET in therapeutic response assessment; Treatment planning for radiation therapy; Future directions of PET imaging for lung cancer; PET for RT-planning in lung cancer; Genomic characterization of lung cancer and its impact on the use and timing of PET in therapeutic response assessment; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Lung Cancer\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: Lung Cancer | v | ||
| Staging of Non–Small-Cell Lung Cancer | v | ||
| Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity | v | ||
| 18F-Fluoro-2-Deoxy-d-Glucose PET/Computed Tomography Evaluation of Lung Cancer in Populations with High Prevalence of Tuber ... | v | ||
| Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment | v | ||
| Treatment Planning for Radiation Therapy | vi | ||
| Prognostic Value of 18F-Fluorodeoxyglucose PET/Computed Tomography in Non–Small-Cell Lung Cancer | vi | ||
| Non–Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose | vi | ||
| Future Directions in PET Imaging of Lung Cancer | vi | ||
| Improved Detection of Small Pulmonary Nodules Through Simultaneous MR/PET Imaging | vii | ||
| Practical Considerations for Clinical PET/MR Imaging | vii | ||
| Diagnostic Imaging and Newer Modalities for Thoracic Diseases: PET/Computed Tomographic Imaging and Endobronchial Ultrasoun ... | vii | ||
| PET CLINICS\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| April 2018 | viii | ||
| July 2018 | viii | ||
| October 2018 | viii | ||
| RECENT ISSUES | viii | ||
| October 2017 | viii | ||
| July 2017 | viii | ||
| April 2017 | viii | ||
| CME Accreditation Page | ix | ||
| PROGRAM OBJECTIVE | ix | ||
| TARGET AUDIENCE | ix | ||
| LEARNING OBJECTIVES | ix | ||
| ACCREDITATION | ix | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | ix | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | ix | ||
| TO ENROLL | ix | ||
| METHOD OF PARTICIPATION | x | ||
| CME INQUIRIES/SPECIAL NEEDS | x | ||
| Preface:\rLung Cancer | xi | ||
| Staging of Non–Small-Cell Lung Cancer | 1 | ||
| Key points | 1 | ||
| TNM CLASSIFICATION | 1 | ||
| T STATUS | 1 | ||
| PRIMARY TUMOR | 2 | ||
| NODAL DISEASE | 3 | ||
| STAGING OF NEWLY DIAGNOSED NON–SMALL-CELL LUNG CANCER | 3 | ||
| COMMENTS | 4 | ||
| THE ROLE OF PET WITH FLUDEOXYGLUCOSE F 18 COMPUTED TOMOGRAPHY SCANNING IN STAGING PATIENTS WITH LUNG CANCER | 4 | ||
| Nodal Disease | 5 | ||
| Endoscopic Transbronchial Ultrasound Examination | 8 | ||
| Comment | 9 | ||
| The Importance of Biopsy | 9 | ||
| SUMMARY | 9 | ||
| REFERENCES | 9 | ||
| Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity | 11 | ||
| Key points | 11 | ||
| PATHOLOGY AND CLINICAL STAGE | 12 | ||
| SIZE OF LESION | 14 | ||
| SUBSOLID NODULES | 15 | ||
| LOW F18-FLUORODEOXYGLUCOSE AVIDITY AS A PROGNOSTIC IMPLICATION | 15 | ||
| SUMMARY | 16 | ||
| REFERENCES | 16 | ||
| 18F-Fluoro-2-Deoxy-d-Glucose PET/Computed Tomography Evaluation of Lung Cancer in Populations with High Prevalence of Tuber ... | 19 | ||
| Key points | 19 | ||
| INTRODUCTION | 19 | ||
| EPIDEMIOLOGY AND RISK FACTORS OF LUNG CANCER | 20 | ||
| EPIDEMIOLOGY AND RISK FACTORS OF TUBERCULOSIS | 20 | ||
| PATHOPHYSIOLOGY OF TUBERCULOSIS IN RELATION TO 18F-FLUORO-2-DEOXY-D-GLUCOSE UPTAKE | 20 | ||
| -GLUCOSE PET/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF LUNG CANCER | 21 | ||
| -GLUCOSE PET/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF PULMONARY TUBERCULOSIS | 23 | ||
| PULMONARY TUBERCULOSIS: THE GREATER MIMICKER OF LUNG CANCER | 25 | ||
| OTHER INFECTIOUS/INFLAMMATORY LESIONS MIMICKING MALIGNANCY | 27 | ||
| SUMMARY | 28 | ||
| REFERENCES | 29 | ||
| Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment | 33 | ||
| Key points | 33 | ||
| INTRODUCTION | 33 | ||
| THE GENOMIC LANDSCAPE OF NON–SMALL CELL LUNG CANCER | 34 | ||
| Genotypes with Available Targeted Therapies | 34 | ||
| Implications of Clonal Evolution and Intratumor Heterogeneity in Drug Resistance | 35 | ||
| Mechanisms of Drug Resistance in ALK Rearranged Non–Small Cell Lung Cancer | 36 | ||
| RESPONSE ASSESSMENT CRITERIA IN LUNG CANCER | 36 | ||
| Limitations of Conventional Response Assessment Criteria in Lung Cancer | 37 | ||
| Metabolic Response Criteria | 37 | ||
| Immune-Related Response Criteria | 37 | ||
| Beyond 18F-Fluorodeoxyglucose: Newer PET Tracers | 37 | ||
| Timing of PET in Therapeutic Response Assessment in Lung Cancer | 38 | ||
| PET DETECTION OF OLIGOPROGRESSIVE DISEASE | 39 | ||
| SUMMARY | 39 | ||
| REFERENCES | 40 | ||
| Treatment Planning for Radiation Therapy | 43 | ||
| Key points | 43 | ||
| INTRODUCTION | 43 | ||
| WHAT PATIENTS ARE SUITABLE FOR CURATIVE-INTENT RADIATION THERAPY? | 44 | ||
| Disease-Related Factors | 44 | ||
| Patient Factors | 46 | ||
| USE OF IMAGING IN STAGING AND SELECTING PATIENTS FOR CURATIVE-INTENT RADIATION THERAPY | 46 | ||
| Mediastinal Nodal Staging | 47 | ||
| Determination of Local Tumor Extent | 47 | ||
| Detection of Distant Metastasis | 47 | ||
| Impact of 18F-fluorodeoxyglucose–PET on overall management strategy of patients with non–small cell lung cancer with radiat ... | 49 | ||
| Timeliness of treatment-planning PET/computed tomography scans | 49 | ||
| Use of PET for Target Volume Definition in Lung Cancer | 49 | ||
| Response-Adapted Therapy and Targeting of Tumor Subvolumes | 50 | ||
| NORMAL TISSUES WITH PET | 52 | ||
| SUMMARY | 53 | ||
| ACKNOWLEDGMENTS | 53 | ||
| REFERENCES | 53 | ||
| Prognostic Value of 18F-Fluorodeoxyglucose PET/Computed Tomography in Non–Small-Cell Lung Cancer | 59 | ||
| Key points | 59 | ||
| MAXIMUM STANDARDIZED UPTAKE VALUE AS A NON–SMALL-CELL LUNG CANCER PROGNOSTICATOR | 60 | ||
| Pretreatment Maximum Standardized Uptake Value | 60 | ||
| Preoperative maximum standardized uptake value | 60 | ||
| Preradiation maximum standardized uptake value | 61 | ||
| Prechemotherapy maximum standardized uptake value | 61 | ||
| Posttreatment Maximum Standardized Uptake Value as an Non–Small-Cell Lung Cancer Prognosticator | 61 | ||
| Maximum standardized uptake value in postinduction/early response | 61 | ||
| Maximum standardized uptake value postradiation/posttreatment | 62 | ||
| Maximum Standardized Uptake Value Controversies | 62 | ||
| BETTER PROGNOSTICATORS | 63 | ||
| Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis are Prognostic | 63 | ||
| Posttreatment Metabolic Tumor Volume and Total Lesion Glycolysis are Prognostic | 63 | ||
| Volume-Based PET Parameters are Better than Maximum Standardized Uptake Value | 64 | ||
| F-FLUORODEOXYGLUCOSE–PET PARAMETERS | 64 | ||
| Changes of 18F-Fluorodeoxyglucose Activity as Prognostic Markers | 64 | ||
| Background Activity–Based PET Metrics as Prognostic Markers | 65 | ||
| THERAPY RESPONSE CRITERIA | 65 | ||
| OF QUANTITATIVE PET PARAMETERS | 67 | ||
| SUMMARY | 68 | ||
| REFERENCES | 68 | ||
| Non–Small-Cell Lung Cancer PET Imaging Beyond F18 Fluorodeoxyglucose | 73 | ||
| Key points | 73 | ||
| INTRODUCTION | 73 | ||
| TRACERS IN PULMONARY NEUROENDOCRINE TUMORS | 74 | ||
| PET IMAGING OF TUMOR PROLIFERATION | 74 | ||
| PET IMAGING OF HYPOXIA | 75 | ||
| PET IMAGING OF ANGIOGENESIS | 76 | ||
| PET TRACERS FOR TARGETED THERAPIES | 77 | ||
| SUMMARY | 79 | ||
| REFERENCES | 79 | ||
| Future Directions in PET Imaging of Lung Cancer | 83 | ||
| Key points | 83 | ||
| INTRODUCTION | 83 | ||
| INFLAMMATION OR TUMOR? | 83 | ||
| PRETREATMENT RESPONSE PREDICTION | 84 | ||
| INTEGRATION OF FUNCTIONAL IMAGING INTO CLINICAL TRIALS | 84 | ||
| ALTERNATIVE APPROVAL AND FUNDING FOR NOVEL PET AGENTS | 85 | ||
| NEW INSTRUMENTATION | 86 | ||
| THERANOSTICS | 86 | ||
| SUMMARY | 87 | ||
| REFERENCES | 87 | ||
| Improved Detection of Small Pulmonary Nodules Through Simultaneous MR/PET Imaging | 89 | ||
| Key points | 89 | ||
| INTRODUCTION | 89 | ||
| LUNG MOTION CORRECTION IN MAGNETIC RESONANCE/PET: PREVIOUS LIMITATIONS | 90 | ||
| Retrospective Motion Correction for Magnetic Resonance/PET Data | 90 | ||
| Prospective Motion Correction for Magnetic Resonance/PET Data | 90 | ||
| METHODS | 91 | ||
| RESULTS | 92 | ||
| DISCUSSION | 93 | ||
| REFERENCES | 93 | ||
| Practical Considerations for Clinical PET/MR Imaging | 97 | ||
| Key points | 97 | ||
| WORKFLOW, PROTOCOLLING, REPORTING AND BILLING | 97 | ||
| MR IMAGING AND RADIATION SAFETY | 99 | ||
| WHOLE-BODY PET/MR IMAGING ACQUISITION | 100 | ||
| Comparison of Whole-Body PET/MR Imaging and PET/Computed Tomography Protocols | 101 | ||
| Sequences | 103 | ||
| Tailoring PET/MR Imaging to the Clinical Application | 105 | ||
| DEDICATED REGIONAL MR IMAGING | 105 | ||
| PET PROTOCOL | 106 | ||
| ARTIFACTS AND PITFALLS | 109 | ||
| SUMMARY | 110 | ||
| REFERENCES | 110 | ||
| Diagnostic Imaging and Newer Modalities for Thoracic Diseases | 113 | ||
| Key points | 113 | ||
| INTRODUCTION | 113 | ||
| NONINVASIVE MODALITIES | 113 | ||
| Computed Tomographic Scans | 113 | ||
| Computed tomographic scans in assessing pulmonary nodules | 115 | ||
| Computed tomographic scan in assessing regional lymph nodes | 116 | ||
| Integrated PET with Computed Tomography | 116 | ||
| Integrated PET/computed tomography to evaluate the primary lesion | 116 | ||
| Integrated PET/computed tomographic scans to evaluate lymph node involvement | 117 | ||
| Integrated PET/computed tomographic scans to delineate metastases | 118 | ||
| Future advances in integrated PET/computed tomographic imaging | 118 | ||
| INVASIVE EVALUATION | 118 | ||
| Computed Tomographic Imaging to Guide Percutaneous Biopsies | 119 | ||
| Endoscopically Directed Biopsies | 119 | ||
| Endobronchial Ultrasound | 120 | ||
| Endoscopic Ultrasound | 121 | ||
| Endobronchial Ultrasound Combined with Esophageal Ultrasound | 121 | ||
| Electromagnetic Navigational Bronchoscopy | 122 | ||
| DISCUSSION | 122 | ||
| SUMMARY | 122 | ||
| REFERENCES | 122 |